Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 710-716 , May 2011

Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants

  • Melhem Solh

      Affiliations

    • Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Claudio Brunstein

      Affiliations

    • Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Shanna Morgan

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Daniel Weisdorf

      Affiliations

    • Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Daniel Weisdorf, MD, Blood and Marrow Transplant Program,Division of Hematology, Oncology and Transplantation,University of Minnesota, Mayo Mail Code 480; 420 Delaware Street SE, Minneapolis, MN 55455

Received 16 July 2010 ,Accepted 21 August 2010.

References 

  1. Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46:289–312
  2. Osterwalder B, Gratwohl A, Reusser P, Tichelli A, Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation. Recent Results Cancer Res. 1988;108:44–52
  3. Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringden O. Blood transfusion in marrow graft recipients. Ann Hematol. 1992;65:66–70
  4. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 362:600–613.
  5. Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringden O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion. 2005;45:1064–1072
  6. Klumpp TR, Herman JH, Innis S, et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996;17:1035–1041
  7. Nevo S, Fuller AK, Zahurak ML, et al. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 10(9) or 20 × 10(9) per L. Transfusion. 2007;47:1700–1709
  8. Nevo S, Fuller AK, Hartley E, Borinsky ME, Vogelsang GB. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 10(9) and 20 × 10(9) per L. Transfusion. 2007;47:801–812
  9. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–909
  10. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337:1870–1875
  11. Wandt H, Frank M, Ehninger G, et al. Link, safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–3606
  12. Aderka D, Praff G, Santo M, Weinberger A, Pinkhas J. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci. 1986;291:147–151
  13. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant. 1996;18:931–935
  14. Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant. 2002;8:569–576
  15. Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol. 2001;8:319–325
  16. Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood. 2008;112:3036–3047
  17. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–1609
  18. Prebet T, Ladaique P, Ferrando M, et al. Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol. 38:55–60.
  19. Brunstein CG, Barker JN, Weisdorf DJ, et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009;43:935–940
  20. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–1577
  21. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88:795–802
  22. Matsuno N, Wake A, Uchida N, et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood. 2009;114:1689–1695
  23. Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006;24:4150–4157
  24. Martino R, Caballero MD, de la Serna J, et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant. 2002;30:63–68
  25. Ivanov V, Faucher C, Mohty M, et al. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion. 2004;44:501–508
  26. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 2001;98:3584–3588
  27. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15:564–573

 Financial disclosure: See Acknowledgments on page 715.

PII: S1083-8791(10)00366-6

doi: 10.1016/j.bbmt.2010.08.017

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 710-716 , May 2011

Article Tools

* Image Usage & Resolution